Filing Flows › iSpecimen (ISPC) › Q2 2025
iSpecimen (ISPC) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
iSpecimen (ISPC) reported revenue of $713K for the second quarter 2025 (Q2 2025), -75% from a year earlier and -33% from the quarter before. Operating margin was -255.4%, net loss $1.0M (146.9% of revenue).
iSpecimen, Q2 2025: revenue $713K (-75% year over year), operating margin -255.4%, net loss $1.0M, operating cash flow −$192K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $713K | -33% | -75% |
| Operating profit | −$1.8M | — | — |
| Net earnings | −$1.0M | — | — |
| Operating cash flow | −$192K | — | — |
What changed
Revenue was $713K in Q2 2025, down 75% year over year and down 33% from the previous quarter. Product was the largest line at 94% of revenue. Product lost $2.2M year over year (down 76%), 101% of the total change.
Operating costs exceeded revenue by $1.8M, an operating margin of -255.4%. Total costs fell 50% while revenue fell 75%. The quarter ended with a net loss of $1.0M, narrower than the previous quarter's $1.7M loss. Non-operating items added $774K, -74% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$192K. Non-cash charges added back $433K of depreciation and amortization and $2K of share-based compensation. Working capital and other items added $420K.
Questions
What was iSpecimen's revenue in the second quarter 2025?
iSpecimen (ISPC) reported revenue of $713K for the second quarter 2025 (Q2 2025), -75% from a year earlier and -33% from the quarter before.
Was iSpecimen profitable in the second quarter 2025?
Operating loss was $1.8M (-255.4% of revenue) and net loss $1.0M.
Source: iSpecimen 10-Q on SEC EDGAR.